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Abstract
Background: Iron deficiency (ID) in patients with chronic heart failure (CHF) is considered an adverse prognostic
factor. We aimed to evaluate if ID in patients with CHF is associated with increased mortality and hospitalizations.
Methods: We evaluated ID in patients with CHF at 3 university hospitals. ID was defined as absolute (ferritin < 100 μg/L)
or functional (transferrin Saturation index < 20% and ferritin between 100 and 299 μg/L). We excluded patients who
received treatment with intravenous Iron or Erythropoietin during follow-up. We evaluated if ID was a predictor of death
or hospitalization due to heart failure or any cause using univariate and multivariate cox regression analysis.
Results: We included 1684 patients, 65% males, 38% diabetics, median age of 72 years, 37% in functional class III-IV and
30% of patients with a left ventricular ejection fraction > 45%. Patients were well treated, with 87% and 88% of patients
receiving renin-angiotensin inhibitors and beta-blockers, respectively. Median transferrin saturation index was 20%,
median ferritin 155 ng/mL and median haemoglobin 13 g/dL. ID was present in 53% of patients; in 35% it was absolute
and in 18% functional. Median follow-up was 20 months. ID was a predictor of death, hospitalization due to heart failure
or to any cause in univariate analysis but not after multivariate analysis. No differences were found between absolute or
functional ID regarding prognosis.
Conclusion: In a real life population of patients with CHF and a high prevalence of heart failure with preserved ejection
fraction, ID did not predict mortality or hospitalizations after adjustment for comorbidities, functional class and
neurohormonal treatment.
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Background
Iron deficiency (ID) affects up to 50% of patients with
chronic heart failure (HF) and has been identified as an
adverse prognostic factor independently of the presence
of anaemia and chronic kidney disease (CKD) [1, 2].
However, in another study of community-dwelling adults
with self-reported heart failure there was no association
between ID and all cause or cardiovascular mortality,
but haemoglobin and C-reactive protein did predict
worse survival [3]. ID frequently overlaps with anaemia
and/or CKD in chronic HF and the presence of ID amp-
lifies mortality risk, either alone or in combination with
anaemia, CKD, or both [2].
Although the pathophysiology behind ID in patients
with chronic HF is not fully understood and is considered
multifactorial [4–6], treatment of ID in these patients has
become a therapeutic goal. Oral iron is not associated with
an increase in exercise capacity in patients with HF and
systolic dysfunction [7]. Recent randomized trials have
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demonstrated how intravenous iron can improve exercise
capacity, cardiac function, symptom severity and quality
of life in patients with chronic HF and left ventricular sys-
tolic dysfunction [8–11]. In the most recent study, the
CONFIRM-HF, the risk of hospitalization due to worsen-
ing heart failure was reduced in the ferric carboxymaltose
arm vs. the placebo-treated arm. However, no study has
evaluated the incidence of hospitalizations due to heart
failure or to any cause in patients with chronic HF and ID.
Given the importance of reducing mortality and hospi-
talizations in patients with chronic HF and that treat-
ment with intravenous iron may reduce hospitalizations,
we aimed to evaluate the prognostic importance of ID in
a large multicenter cohort of ambulatory patients with
chronic HF, focusing on mortality and hospitalizations
due to worsening heart failure or to any cause.
Methods
Study design
This is a retrospective observational cohort study of pa-
tients with heart failure in whom we evaluated the pres-
ence of ID and whether ID was associated with
re-hospitalizations or mortality during follow-up.
Component population
The study population consisted of 2495 consecutive pa-
tients with stable chronic HF prospectively enrolled at 3
multidisciplinary heart failure (HF) units from 3 tertiary
hospitals in Spain from 2005 to 2012. Patients had to be
diagnosed of HF according to the European Society of
Cardiology diagnostic criteria [12]. We defined HF with
preserved LVEF (HFPEF) as the presence of symptoms
of HF with a left ventricular ejection fraction ≥50% and
an objective evidence of cardiac dysfunction (enlarged
left atrium, diastolic dysfunction or elevated natriuretic
peptides). We excluded patients without iron status
assessed at entry and those with significant primary valvu-
lar or pericardial disease. Of the remaining 2172 patients,
we excluded those who received treatment with intraven-
ous iron or subcutaneous erythropoetin at any time point
during follow-up, after review of the pharmacy records, as
this treatment could influence outcomes. This left 1684
patients for analysis. Patients were treated according to
the European Society of Cardiology guidelines [12].
Written informed consent was obtained from each pa-
tient. The investigation conforms with the principles
outlined in the Declaration of Helsinki. The local ethic
committees approved the study protocol.
Pooled methodology
The pooled data for the present study were assessed at a
patient level and collected prospectively. The end points
for the present study were all cause mortality, first
hospitalization due to HF and first hospitalization due to
any cause after inclusion in the HF unit. Vital status and
hospitalizations were assessed by review of the clinical da-
tabases, hospital records or direct contact with patients or
relatives. Follow-up duration was until death or up to the
last visit in the out patient clinic before October 2015. For
patients lost to follow-up, we contacted the patient or the
family by telephone and determined vital status and hospi-
talizations. For patients that could not be contacted by
telephone we accessed the electronic clinical history of the
hospital and of the primary care health system and deter-
mined vital status and hospitalizations. If despite all these
efforts, no information regarding hospitalizations and
death could be obtained, end of follow-up was determined
to be the last time the patient had been to the out patient
clinic. Five patients received a heart transplant during
follow-up and this was recorded as death and end of
follow-up. No patient received a ventricular assist device.
Iron status and other laboratory measurements
The following blood biomarkers reflecting iron status were
measured at study entry: Serum iron (ug/dL) was measured
using spectrophotometry, serum ferritin (ng/mL) and trans-
ferrin (mg/dL) were measured using immunoturbidimetry.
Transferrin saturation index (TSAT) was estimated using
the formula: TSAT= serum iron (ug/dL)/[serum transferrin
(mg/dL) × 1.25] [13]. ID was defined as absolute when fer-
ritin < 100 ng/ml and functional when TSAT < 20% with
ferritin 100–299 ng/ml [8].
Haemoglobin was measured using impedance laser
colorimetry and anaemia was defined as Haemoglobin <
12 g/dL in women and Haemoglobin < 13 g/dL in men.
Concentrations of N-terminal pro-brain-type natriuretic
peptide (NT-proBNP) were measured using an immuno-
assay based on electrochemiluminescence on the Elecsys
Fig. 1 Flowchart of the study population. 105 of patients treated
with erythropoietin were also treated with intravenous iron
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System (Roche Diagnostics, Basel, Switzerland). Renal
function was assessed with the estimated glomerular
filtration rate using the abbreviated Modification of Diet
in Renal Disease equation.
Statistical analysis
Continuous variables were explored for normal distribu-
tion according to histograms and the Shapiro-Wilk test.
The comparison of quantitative variables between the 2
groups was done using the Student-t test for normally
distributed variables and the Mann-Whitney U test for
non-normally distributed variables. The chi-square test
was used for categorical variables and Fisher’s exact test
when cells had an expected count of less than 5.
The continuous variables that had a very skewed dis-
tribution, such as the TSAT, Ferritin and NT-proBNP
underwent logarithmic transformation. The resulting
variables are referred to as: logTSAT, logFerritin and
logNT-proBNP. In order to assess if variables introduced
in the multivariate regression analysis were highly corre-
lated we evaluated collinearity using the variance infla-
tion factor. The maximal variance inflation factor found
Table 1 Baseline variables according to iron deficiency
Variables Overall N = 1684 No ID N = 786 ID N = 898 P value
Age (years) 72 (61–79) 70 (58–78) 73 (63–79) < 0.0001
Female gender 588 (35) 207 (26) 381 (42) < 0.0001
BMI (kg/m2) 27 (24–30) 30 (27–34) 31 (27–36) 0.011
Systolic BP (mm Hg) 120 (108–139) 118 (105–133) 125 (110–140) < 0.0001
Heart rate (bpm) 70 (62–80) 70 (60–80) 70 (62–80) 0.398
NYHA Class III-IV 592 (35) 218 (28) 374 (42) < 0.0001
LVEF (%) 35 (27–50) 35 (27–48) 36 (28–53) 0.032
HFPEF 428 (25) 182 (23) 246 (27) 0.046
Ischaemic aetiology 738 (44) 331 (42) 407 (45) 0.185
Hypertension 1136 (68) 492 (63) 644 (72) < 0.0001
Diabetes Mellitus 639 (38) 262 (33) 377 (42) < 0.0001
COPD 318 (19) 158 (20) 160 (18) 0.232
Treatment
ACE-I or ARB 1457 (87) 695 (89) 762 (85) 0.019
Beta blockers 1474 (88) 690 (88) 784 (87) 0.766
MRAs 716 (43) 357 (45) 359 (40) 0.024
Digoxin 395 (23) 184 (23) 211 (24) 0.966
Oral anticoagulation 755 (45) 356 (45) 399 (44) 0.723
Antiplatelet 879 (52) 412 (52) 467 (52) 0.884
Diuretics 1458 (87) 661 (84) 797 (89) 0.001
ICD 136 (8) 64 (8) 72 (8) 0.933
Resynchronization 77 (5) 35 (5) 42 (5) 0.826
Laboratory values
Haemoglobin (g/dL) 13.0 (11.7–14.3) 13.4 (12.0–14.7) 12.7 (11.5–13.9) < 0.0001
eGFR (ml/min/1.73 m2) 53 (37–71) 56 (38–75) 52 (36–68) 0.032
Ferritin (ng/mL) 155 (72–276) 276 (172–435) 76 (43–141) < 0.0001
Transferrin (mg/dL) 261 (224–313) 245 (213–288) 276 (239–330) < 0.0001
Serum iron (ug/dL) 73 (51–99) 90 (71–116) 59 (44–79) < 0.0001
TSAT (%) 20 (15–28) 26 (22–34) 16 (12–19) < 0.0001
NTproBNP (ng/L) 1355 (536–3171) 1111 (488–2747) 1584 (609–3597) < 0.0001
Sodium (mmol/L) 140 (138–142) 140 (138–142) 140 (138–142) 0.011
Continuous variables are expressed as median and interquartile range (IQR). Categorical variables are expressed as number and percentage
ID Iron deficiency, BMI Body mass index, NYHA New York Heart Association, LVEF Left ventricular ejection fraction, HFPEF Heart failure with preserved ejection
fraction, COPD Chronic obstructive pulmonary disease, ACE-I Angiotensin converting enzyme inhibitor, ARB Angiotensin II receptor blocker, MRA Mineralocorticoid
receptor antagonist, ICD Implantable cardioverter defibrillator, eGFR estimated glomerular filtration rate, TSAT Transferrin saturation, NTproBNP N-terminal pro-brain
natriuretic peptide
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among baseline variables was 1.5, indicating a low de-
gree of collinearity.
To evaluate predictors of ID we used multivariate
logistic regression analysis. All baseline variables with a
significant univariate association (p < 0.10) or deemed to
be clinically relevant were entered in a step-wise back-
ward multivariable model with an exclusion criteria of
p > 0.10. Additional bootstrap analysis (1000 cycles) of
the multivariate model was performed to measure accur-
acy of the estimated model. The R2 value for the multi-
variate model was also calculated.
Incidence ratio of death and hospitalizations due to
HF or any cause were determined dividing the incidence
rate of events in patients with ID vs. without ID. Signifi-
cance was assessed using the Mantel-Haenszel Chi
square test.
Survival and time to first hospitalization due to heart
failure or any cause were evaluated using Kaplan Meier
survival curves. We evaluated if ID was a predictor of
survival or hospitalization using univariate Cox propor-
tional hazard regression analysis. With the variables that
were significant in the univariate analysis (p < 0.10) and
those that were deemed to be clinically relevant, we then
performed backward step multivariate Cox proportional
hazard analysis with an exclusion criteria of p > 0.10. ID is
forced in to the final multivariate model given that it is
the purpose of our study. The proportionality assumption
for the Cox regression analysis was evaluated using re-
sidual analysis. Significance was set at p < 0.05 (2 tailed)
and SPSS version 18 and Stata 14 were used to perform all
statistical evaluations.
Results
We included 1684 patients in the analysis (see flowchart
in Fig. 1), whose baseline characteristics are shown in
Table 1. ID was present at inclusion in 898 (53%)
patients. In 35% it was absolute ID and in 18% func-
tional ID. There were 953 (57%) patients who were not
Table 2 Predictors of iron deficiency using logistic regression analysis
Variables Univariate OR P value Multivariate OR P value
Age (per 5 years) 1.09 (1.05–1.13) < 0.001
Female sex 2.05 (1.67–2.53) 0.396 1.62 (1.29–2.03) < 0.001
Hypertension 1.50 (1.23–1.85) < 0.001
Diabetes Mellitus 1.44 (1.18–1.76) < 0.001
COPD 0.86 (0.67–1.10) 0.223
HFPEF 1.25 (1.00–1.56) 0.047
Ischaemic aetiology 1.15 (0.94–1.39) 0.175
NYHA class III-IV 1.84 (1.50–2.26) < 0.001 1.50 (1.20–1.88) < 0.001
Systolic BP (per 10 mmHg) 1.11 (1.06–1.16) < 0.001 1.09 (1.04–1.14) < 0.001
Heart rate (per 10 bpm) 1.03 (0.97–1.10) 0.379
BMI (1 kg/m2) 1.03 (1.01–1.04) 0.008 1.03 (1.00–1.05) 0.018
ACE-I or ARB 0.71 (0.53–0.95) 0.021
Beta blockers 0.96 (0.72–1.28) 0.781
Diuretics 1.50 (1.13–1.98) 0.005
MRAs 0.81 (0.66–0.98) 0.028
Digoxin 1.00 (0.80–1.26) 0.988
Oral anticoagulants 0.96 (0.79–1.17) 0.690
Antiplatelet 0.99 (0.82–1.20) 0.921
ICD 1.02 (0.71–1.44) 0.94
Haemoglobin (per 1 g/dL) 0.82 (0.78–0.87) < 0.001 0.87 (0.82–0.92) < 0.001
Log NT-proBNP (per 1 SD) 1.20 (1.09–1.33) < 0.001 1.12 (0.99–1.25) 0.051
Sodium (per 5 mmol/L) 1.17 (1.02–1.34) 0.030
eGFR (per 5 ml/min/1.73m2) 0.98 (0.96–0.99) 0.016
OR Odds Ratio, COPD Chronic Obstructive Pulmonary Disease, HFPEF Heart failure with preserved ejection fraction, NYHA New York Heart Association, BP Blood
pressure, BMI Body mass index, ACE-I Angiotensin converting enzyme inhibitor, ARB Angiotensin II receptor blocker, MRAs Mineralocorticoid receptor antagonists,
ICD Implantable cardioverter defibrillator, Log Logarithmic transformation, NTproBNP N-terminal pro-brain natriuretic peptide, SD Standard deviation, eGFR
Estimated glomerular filtration rate
Variables introduced in the multivariate model were: Age, gender, hypertension, diabetes mellitus, COPD, HFPEF, NYHA functional class III-IV, systolic BP, heart
rate, BMI, haemoglobin, logNT-proBNP, eGFR, sodium, treatment with beta blockers, ACE-i/ARBs, diuretics and MRAs
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anaemic and ID was present in 460 (48%) of these. Of
the 731 patients with anaemia, ID was present in 438
(60%).
Predictors of ID after multivariate analysis are shown
in Table 2. The R2 for the multivariate model was 0.05
(5%). Median follow-up was 20 (interquartile range: 12–
47) months.
Iron deficiency and mortality
Patients with ID had 307 (34%) deaths with an incidence
rate of 0.134 per year compared with those without ID,
who had 212 (27%) deaths, with an Incidence Rate of
0.101 per year. The incidence ratio was 1.32 (95% confi-
dence interval: 1.11–1.57; p = 0.0017). Both absolute and
functional ID had similar mortality rates of 0.145 and
0.128 per year, respectively, p = 0.29. When we analysed
both components of the definition of ID, lower logTSAT
predicted mortality but not logFerritin. ID was not a
predictor of mortality in multivariate analysis. Table 3
shows the hazard ratios for mortality in our cohort of
patients using univariate and multivariate cox regression
analysis. When we introduced logTSAT in the multivari-
ate model, instead of the usual definition of ID, it also
was not a significant predictor of mortality. Figure 2
shows no differences in the survival curves stratified for
ID after adjustment for the covariates that were signifi-
cant in the multivariate model.
Iron deficiency and hospitalizations due to heart failure
Patients with ID had 246 (27%) hospitalizations due to
HF with an incidence rate of 0.121 per year compared
with those without ID, who had 182 (23%) hospitaliza-
tions due HF, with an incidence rate of 0.097 per year.
The incidence ratio was 1.24 (95% confidence interval:
1.03–1.51; p = 0.025). There was no significant difference
in the incidence rate of hospitalizations due to heart fail-
ure between patients with functional or absolute ID:
0.110 and 0.125 per year respectively, p = 0.37. ID was
not a predictor of hospitalization due to heart failure
after multivariate analysis. Table 4 shows predictors of
hospitalization due to HF after univariate and multivari-
ate adjustment. Figure 3 shows the survival curves for
Table 3 Predictors of mortality using cox regression analysis
Variables Univariate HR P value Multivariate HR P value
Age (per 5 years) 1.36 (1.30–1.42) < 0.001 1.21 (1.16–1.27) < 0.001
Female sex 1.08 (0.90–1.30) 0.39 0.65 (0.54–0.79) < 0.001
Hypertension 1.35 (1.12–1.63) 0.002
Diabetes Mellitus 1.51 (1.27–1.80) < 0.001 1.30 (1.08–1.55) 0.005
COPD 1.63 (1.33–1.99) < 0.001
HFPEF 1.11 (0.90–1.36) 0.34
Ischaemic aetiology 1.09 (0.92–1.30) 0.33
NYHA class III-IV 3.14 (2.63–3.74) < 0.001 1.85 (1.53–2.24) < 0.001
Systolic BP (per 10 mmHg) 0.97 (0.93–1.01) 0.112
Heart rate (per 10 bpm) 1.09 (1.03–1.16) 0.004
BMI (1 kg/m2) 0.96 (0.95–0.98) < 0.001
ACE-I or ARB 0.37 (0.29–0.46) < 0.001 0.70 (0.55–0.89) 0.004
Beta blockers 0.41 (0.33–0.51) < 0.001 0.59 (0.47–0.74) < 0.001
Diuretics 2.46 (1.77–3.42) < 0.001 1.66 (1.19–2.31) 0.005
MRAs 0.97 (0.82–1.16) 0.77
Digoxin 1.26 (1.05–1.52) 0.015
ICD 0.72 (0.52–0.98) 0.039
Iron deficiency 1.32 (1.11–1.57) 0.002 1.09 (0.91–1.31) 0.337
Haemoglobin (per 1 g/dL) 0.78 (0.75–0.82) < 0.001 0.90 (0.85–0.95) < 0.001
Log NT-proBNP (per 1 SD) 1.93 (1.76–2.11) < 0.001 1.49 (1.34–1.66) < 0.001
Sodium (per 5 mmol/L) 0.78 (0.69–0.88) < 0.001 0.96 (0.94–0.99) 0.003
eGFR (per 5 ml/min/1.73m2) 0.89 (0.87–0.91) < 0.001
HR Hazard Ratio, COPD Chronic Obstructive Pulmonary Disease, HFPEF Heart failure with preserved ejection fraction, NYHA New York Heart Association, BP Blood
pressure, BMI Body mass index, ACE-I Angiotensin converting enzyme inhibitor, ARB Angiotensin II receptor blocker, MRAs Mineralocorticoid receptor antagonists,
ICD Implantable cardioverter defibrillator, Log Logarithmic transformation, NTproBNP N-terminal pro-brain natriuretic peptide, SD Standard deviation, eGFR
Estimated glomerular filtration rate
Variables introduced in the multivariate model were: Age, gender, ischaemic aetiology, systolic BP, HFPEF, diabetes mellitus, hypertension, COPD, BMI, NYHA
functional class III-IV, haemoglobin, logNT-proBNP, eGFR, sodium, heart rate, treatment with beta blockers, ACE-i/ARBs, diuretics, digoxin and an ICD
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Fig. 2 Survival curves stratified for ID after adjustment for the covariates that are significant in the multivariate model: Age, sex, diabetes mellitus,
New York Heart Association class III-IV, haemoglobin, logarithmic transformation of N-terminal pro-brain natriuretic peptide, serum sodium, and
treatment with an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, beta blockers and diuretics
Table 4 Predictors of heart failure hospitalization using Cox regression analysis
Variables Univariate HR P value Multivariate HR P value
Age (per 5 years) 1.23 (1.18–1.29) < 0.001 1.11 (1.05–1.17) < 0.001
Female sex 1.50 (1.25–1.83) < 0.001
Hypertension 1.47 (1.19–1.81) < 0.001
Diabetes Mellitus 1.46 (1.20–1.77) < 0.001 1.26 (1.03–1.54) 0.026
COPD 1.76 (1.41–2.19) < 0.001 1.63 (1.28–2.07) < 0.001
HFPEF 1.60 (1.30–1.97) < 0.001 1.67 (1.31–2.18) < 0.001
Ischaemic aetiology 1.14 (0.95–1.38) 0.166 1.40 (1.12–1.73) 0.003
NYHA class III-IV 2.55 (2.10–3.09) < 0.001 1.64 (1.33–2.03) < 0.001
Systolic BP (per 10 mmHg) 0.97 (0.93–1.01) 0.123
Heart rate (per 10 bpm) 1.09 (1.03–1.16) 0.005
BMI (per 1 kg/m2) 0.99 (0.97–1.01) 0.21
ACE-I or ARB 0.47 (0.37–0.61) < 0.001
Beta blockers 0.46 (0.36–0.58) < 0.001 0.71 (0.54–0.93) 0.013
Diuretics 3.47 (2.28–5.28) < 0.001 2.53 (1.64–3.91) < 0.001
MRAs 1.10 (0.91–1.33) 0.327
Digoxin 1.13 (0.91–1.40) 0.263
ICD 0.91 (0.66–1.27) 0.581
Iron deficiency 1.21 (1.00–1.47) 0.047 0.96 (0.78–1.17) 0.677
Haemoglobin (per 1 g/dL) 0.84 (0.80–0.89) < 0.001
Log NT-proBNP (per 1 SD) 2.00 (1.87–2.15) < 0.001 1.49 (1.32–1.68) < 0.001
Sodium (per 5 mmol/L) 0.93 (0.81–1.07) 0.328
eGFR (per 5 ml/min/1.73m2) 0.95 (0.93–0.97) < 0.001
HR Hazard Ratio, COPD Chronic Obstructive Pulmonary Disease, HFPEF Heart failure with preserved ejection fraction, NYHA New York Heart Association, BP Blood
pressure, BMI Body mass index, ACE-I Angiotensin converting enzyme inhibitor, ARB Angiotensin II receptor blocker, MRAs Mineralocorticoid receptor antagonists,
ICD Implantable cardioverter defibrillator, Log Logarithmic transformation, NTproBNP N-terminal pro-brain natriuretic peptide, SD Standard deviation, eGFR
Estimated glomerular filtration rate
Variables introduced in the multivariate model were gender, age, diabetes mellitus, hypertension, BMI, ischaemic aeetiology, systolic blood pressure, COPD, HFPEF,
heart rate, NYHA functional class III-IV, haemoglobin, logNT-proBNP, eGFR and treatment with ACE-i/ARBs, beta blockers, diuretics and MRAs
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hospitalization due to HF stratified for ID and adjusted
for the covariates that were significant in the multivari-
ate model.
Iron deficiency and hospitalizations due to any cause
Patients with ID had 465 (52%) hospitalizations due to
any cause with an Incidence Rate of 0.284 per year com-
pared with those without ID, who had 363 (46%) hospi-
talizations due to any cause, with an incidence rate of
0.226 per year. The incidence ratio was 1.26 (95% confi-
dence interval: 1.09–1.44; p = 0.001).
Patients with functional ID had a rate of hospitaliza-
tions due to any cause of 0.266 per year compared with
0.290 per year in those with absolute ID, p = 0.36. ID
was not a predictor of hospitalization due to any cause
after multivariate analysis. Table 5 shows the predictors
of hospitalization due to any cause after univariate and
multivariate adjustment. Figure 4 shows the survival
curves for hospitalization due to any cause stratified for
ID and adjusted for the covariates that were significant
in the multivariate model.
Discussion
The main findings of our study are:
1. ID was present in more than half of a large cohort
of ambulatory patients with chronic HF.
2. ID did not predict mortality after multivariate
adjustment.
3. ID did not predict increased hospitalizations due to
heart failure or due to any cause after multivariate
adjustment.
ID was very prevalent in our cohort of patients with
chronic HF and most of it was due to absolute ID.
Predictors of ID after multivariate analysis were female
gender, a higher body mass index, more advanced func-
tional class, increased systolic blood pressure and lower
haemoglobin values. These findings are comparable to
previous findings from other groups [1–3, 14].
Iron deficiency and mortality
ID has been shown to be a marker of increased mor-
tality independently of anaemia and CKD [1, 2, 14],
but in our study we were not able to demonstrate it
after multivariate analysis. However haemoglobin
remained a significant predictor of mortality, as in
the study by Parikh et al. [3]. We can only
hypothesize why this is, but one major difference is
that in our study the number of patients with HFPEF
was significant compared with none in the study by
Jankowska et al. [1] and 13% in the study by Klip et
al. [14]. In the study by Parikh et al. [3] this data is
unknown but given the relatively high mean systolic
blood pressure, large proportion of women and age of
the population it is likely that many of the partici-
pants had HFPEF. When we analyzed if ID was a pre-
dictor of mortality only in patients with systolic
dysfunction, in our cohort it was not significant in
Fig. 3 Survival curves for hospitalization due to HF stratified for ID after adjustment for the covariates that are significant in the multivariate
model: Age, diabetes mellitus, chronic pulmonary obstructive disease, heart failure with preserved ejection fraction, ischaemic aetiology, New York
Heart Association class III-IV, logarithmic transformation of N-terminal pro-brain natriuretic peptide, and treatment with an angiotensin converting
enzyme inhibitor or angiotensin II receptor blocker, beta blockers and diuretics
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multivariate analysis. Our patients were more likely to
be older and had more CKD and anaemia compared
to those studied in the 3 previously mentioned co-
horts and this may imply that other factors besides
ID may be more important in predicting mortality in
our patients. The variables that predicted mortality in
our patients are otherwise not different from those
previously described in the literature [9, 15].
We used the definition of ID according to the
FAIR-HF trial [8]. However, diagnosis based on TSAT
and ferritin may be inadequate in advanced disease or
acute HF, where ferritin becomes an unreliable marker
[16]. In our cohort of ambulatory patients with chronic
HF, ferritin did not predict mortality in univariate ana-
lysis and the driver of adverse prognosis was the TSAT.
Iron deficiency and hospitalizations
Hospitalizations due to HF are frequent in patients with
chronic HF and linked with increased mortality [17], im-
pairment of patient’s quality of life and an economic bur-
den for the health system [18]. Although ID has been
shown to be a key determinant of health-related quality of
life in patients with chronic HF [19], we are not aware that
the association between ID and increased risk of hospitali-
zations due to HF or due to any cause has been studied in
patients with chronic HF. Our study is the first to do so,
and we have shown that ID was associated with hospitali-
zations due to HF in univariate analysis but not after
multivariate analysis. When we looked at predictors of
hospitalization due to HF we found that they were very
similar to those that predicted mortality. The only differ-
ence being that lower serum sodium and lower haemoglo-
bin predicted mortality but not hospitalizations due to
HF. On the other hand, chronic obstructive pulmonary
disease, HFPEF and ischaemic etiology were associated
with increased risk of hospitalization due to HF but not
with mortality. Patients with chronic HF such as those
seen in our study and in recent registries have many co-
morbidities [20], and hospitalizations may be related to
these comorbidities. Therefore, we thought it would be in-
teresting to look at hospitalizations due to any cause. ID
was a predictor of hospitalizations due to any cause in
Table 5 Predictors of hospitalization due to any cause using Cox regression analysis
Variables Univariate HR P value Multivariate HR P value
Age (per 5 years) 1.17 (1.13–1.20) < 0.001 1.06 (1.02–1.09) 0.001
Female sex 1.29 (1.12–1.45) < 0.001
Hypertension 1.42 (1.22–1.65) < 0.001
Diabetes Mellitus 1.46 (1.27–1.68) < 0.001 1.23 (1.06–1.42) 0.006
COPD 1.56 (1.32–1.84) < 0.001 1.44 (1.21–1.71) < 0.001
HFPEF 1.40 (1.20–1.63) < 0.001 1.44 (1.21–1.73) < 0.001
Ischaemic aetiology 1.16 (1.01–1.33) 0.032 1.32 (1.14–1.54) < 0.001
NYHA class III-IV 2.03 (1.77–2.34) < 0.001 1.40 (1.20–1.64) < 0.001
Systolic BP (per 10 mmHg) 1.01 (0.98–1.04) 0.522
Heart rate (per 10 bpm) 1.13 (1.08–1.19) < 0.001 1.07 (1.02–1.12) 0.006
BMI (per 1 kg/m2) 0.99 (0.97–0.99) 0.033
ACE-I or ARB 0.50 (0.41–0.61) < 0.001 0.80 (0.65–0.98) 0.030
Beta blockers 0.51 (0.43–0.62) < 0.001 0.69 (0.57–0.86) 0.001
Diuretics 1.70 (1.36–2.12) < 0.001 1.31 (1.04–1.65) 0.022
MRAs 0.95 (0.83–1.09) 0.488
Digoxin 1.01 (0.86–1.18) 0.940
ICD 0.88 (0.69–1.12) 0.284
Iron deficiency 1.21 (1.05–1.39) 0.007 0.99 (0.86–1.14) 0.857
Haemoglobin (per 1 g/dL) 0.85 (0.81–0.88) < 0.001 0.94 (0.90–0.98) 0.002
LogNT-proBNP (per 1 SD) 1.53 (1.42–1.64) < 0.001 1.31 (1.20–1.42) < 0.001
Sodium (per 5 mmol/L) 0.89 (0.80–0.98) 0.023
eGFR (per 5 ml/min/1.73m2) 0.95 (0.94–0.96) < 0.001
HR Hazard Ratio, COPD Chronic Obstructive Pulmonary Disease, HFPEF Heart failure with preserved ejection fraction, NYHA New York Heart Association, BP Blood
pressure, bpm beats per minute, BMI Body mass index, ACE-I Angiotensin converting enzyme inhibitor, ARB Angiotensin II receptor blocker, MRAs Mineralocorticoid
receptor antagonists, ICD Implantable cardioverter defibrillator, Log Logarithmic transformation, NTproBNP N-terminal pro-brain natriuretic peptide, SD Standard
deviation, eGFR Estimated glomerular filtration rate
We included the following variables in the multivariate analysis: Haemoglobin, sex, age, HFPEF, BMI, Diabetes Mellitus, Hypertension, COPD, ischaemic aetiology,
logNTproBNP, eGFR, serum sodium, systolic BP, heart rate, NYHA functional class III-IV and treatment with ACE-I/ARB, Beta-blockers and diuretics
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univariate analysis, but again not after multivariate ana-
lysis. Predictors of hospitalization due to any cause were
multiple and included all that predicted mortality and all
that predicted hospitalizations due to HF, except for fe-
male sex and serum sodium, but with the addition of heart
rate. What stands out from our analysis is that HFPEF
was associated with a higher risk of hospitalizations due to
heart failure or to any cause, and this may be related not
so much to heart failure itself but to the increased cardio-
vascular and non-cardiovascular comorbidities of patients
with HFPEF [21]. One comorbidity that is particularly
prevalent in HFPEF is chronic pulmonary obstructive dis-
ease [22], and it is notable that in our cohort it was
strongly associated with increased hospitalizations due to
HF and to any cause but not with mortality, as has been
shown in previous studies of patients with HF [23, 24].
It is plausible that in our cohort, other factors might
diminish the importance of ID as a predictor of hospital-
izations. However, our patient population clearly resem-
bles the usual patients seen in clinical practice [18] and
our results issue a word of caution in extrapolating that
ID is linked with increased hospitalizations either due to
HF or to any cause. Therefore, further studies are
needed to evaluate this association, and in this direction,
a report linking ID with 30 days readmission in patients
with acute heart failure was recently published [25].
Iron deficiency in non-anaemic patients
In the FAIR-HF trial, treatment of ID with ferric carbox-
imaltose in patients with chronic HF was equally
efficacious in anaemic and in non-anaemic patients [26].
Given the fact that in our study, anaemia but not ID pre-
dicted mortality, we explored the association of ID with
prognosis in non-anaemic patients. Although ID pre-
dicted increased mortality and hospitalizations in univar-
iate analysis, this association did not hold up in
multivariate analysis.
Limitations
We did not measure other markers of ID, such as the
soluble transferrin receptor, hepcidin or the ferritin
index that may better evaluate iron metabolism in
patients with chronic heart failure [5, 27, 28]. We also
did not assess C-reactive protein, high-sensitivity cardiac
troponin T, and high-sensitivity soluble ST2, which have
been associated with increased mortality in patients with
chronic HF [3, 15]. We had no information regarding
other non-cardiovascular comorbidities such as cancer
or liver disease that could be potential confounders of
outcomes in such an elderly population.
We excluded from the analysis patients that received
treatment with intravenous iron or erythropoietin, creat-
ing a possible bias. However, this treatment was not
approved by the guidelines at the time the study was
performed and given that both these treatments could
influence ID, we preferred to exclude these patients.
When assessing hospitalizations we did not look at
recurrent number of hospitalizations, and this is also an
important outcome that influences quality of life in pa-
tients with HF.
Fig. 4 Survival curves for hospitalization due to any cause stratified for ID after adjustment for the covariates that are significant in the multivariate
model: Age, diabetes mellitus, chronic pulmonary obstructive disease, heart failure with preserved ejection fraction, New York Heart Association class
III-IV, heart rate, haemoglobin, logarithmic transformation of N-terminal pro-brain natriuretic peptide, and treatment with an angiotensin converting
enzyme inhibitor or angiotensin II receptor blocker, beta blockers and diuretics
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Conclusions
In a contemporary cohort of patients with chronic HF,
ID was present in more than half of the patients. How-
ever, its presence was not a predictor of mortality or
hospitalizations due to HF or to any cause after multi-
variate adjustment. Further studies are needed to assess
the prognostic significance of ID in real life patients with
chronic HF and where HFPEF is increasingly prevalent.
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